Precision LNP Formulation Design and Optimization for mRNA Therapeutics
Overview
Lipid nanoparticle (LNP) formulation is a critical determinant of mRNA therapeutic efficacy, yet optimizing lipid composition, N/P ratio, and manufacturing parameters remains a resource-intensive challenge. Our LNP formulation design and optimization service integrates high-throughput AI-assisted screening with deep formulation expertise to rapidly generate customized LNPs that achieve high encapsulation efficiency, favorable physicochemical properties, and potent in vivo expression.
The design of LNPs involves selecting appropriate ionizable lipids, helper lipids, cholesterol, and PEG-lipids, each influencing particle size, surface charge, stability, and cellular uptake. Traditional trial-and-error approaches are inefficient and often fail to identify the optimal formulation for a given mRNA cargo. Our platform leverages machine learning to predict the performance of thousands of lipid combinations, drastically reducing the number of experimental iterations required.
We begin with a comprehensive understanding of your mRNA payload—its length, structure, and stability profile—then employ AI algorithms to predict the most promising ionizable lipids and lipid ratios. From there, our team synthesizes and characterizes candidate LNPs, measuring key attributes such as particle size, polydispersity, zeta potential, encapsulation efficiency, and in vitro/in vivo transfection efficiency. Iterative optimization cycles refine the formulation until performance targets are met.
This service is designed for biotech startups and mid-size pharmaceutical companies that lack the internal infrastructure to systematically optimize LNP formulations. By partnering with us, you gain access to state-of-the-art high-throughput screening, computational modeling, and analytical characterization—all integrated into a single streamlined workflow.
Integrated LNP Formulation Platform
AI-Driven Lipid Screening
Our machine learning framework predicts the performance of ionizable lipids and lipid combinations, enabling high-throughput identification of top-performing candidates for your specific mRNA cargo. This AI-assisted approach reduces experimental burden and accelerates the path to an optimized LNP.
Customizable Lipid Composition
We tailor the ionizable lipid, helper lipid, cholesterol, and PEG-lipid ratios to meet your delivery requirements. Whether you need enhanced endosomal escape, targeted tissue delivery, or improved stability, our formulation design can be adjusted to match your desired profile.
Process Parameter Optimization
We optimize critical process parameters such as N/P ratio, microfluidic mixing conditions, and downstream concentration steps to achieve consistent particle size, high encapsulation efficiency, and scalability. Our approach uses Design of Experiments (DoE) to efficiently identify robust conditions.
Comprehensive Characterization
We provide full physicochemical and biological characterization of each LNP formulation, including particle size, polydispersity, zeta potential, encapsulation efficiency, in vitro transfection in relevant cell lines, and in vivo biodistribution studies. Data-rich reports support your regulatory filings and IND-enabling studies.
End-to-End Service Integration
From mRNA synthesis and LNP formulation to fill & finish, we can support every stage of your mRNA-LNP production. Our integrated platform reduces handoffs and accelerates your timeline from candidate selection to preclinical testing.
Supported Payload Types
Our LNP formulation platform is designed to accommodate a wide range of nucleic acid and small molecule payloads, enabling broad applicability across therapeutic modalities.
- mRNA: Optimized for full-length mRNA, including self-amplifying and modified mRNA, with high encapsulation efficiency and potent in vivo expression.
- siRNA: Formulations tailored for small interfering RNA, achieving efficient endosomal escape and gene silencing in target tissues.
- DNA: Plasmid DNA and minicircle DNA delivery with LNP formulations designed for nuclear delivery and sustained transgene expression.
- Peptides / Proteins: Delivery of peptide and protein therapeutics using LNPs that protect the payload from degradation and facilitate intracellular delivery.
- Combination Cargos: Co-delivery of multiple payloads, such as mRNA + siRNA or therapeutic protein + mRNA, enabling synergistic therapeutic strategies.
Our LNP Formulation Development Workflow
We follow a structured, iterative process to ensure that every LNP formulation meets your performance targets. The workflow is designed to be transparent, data-driven, and tailored to your specific cargo and delivery requirements.
- Initial Consultation & Cargo Assessment: We review your mRNA payload characteristics, desired delivery route, target cell type, and performance criteria. This phase defines the project scope and establishes success metrics for formulation optimization.
- AI-Assisted Design & Lipid Screening: Our machine learning framework screens a library of ionizable lipids and lipid combinations, predicting the most promising candidates for your specific cargo. We then generate a focused set of prototype formulations for experimental testing.
- Formulation Synthesis & Characterization: We synthesize the selected LNP formulations using microfluidic mixing and characterize them for particle size, polydispersity, zeta potential, encapsulation efficiency, and stability. In vitro transfection assays in relevant cell lines provide an initial readout of delivery performance.
- Iterative Optimization & Final Delivery: Based on characterization results, we refine lipid ratios, N/P ratio, and process parameters through additional Design of Experiments (DoE) cycles. The optimized formulation is then scaled up, and a final report is delivered with full characterization data and recommended storage conditions.
Data-Driven Iteration
Each cycle of formulation screening, characterization, and optimization generates quantitative data that feeds back into our AI models, continuously improving predictive accuracy and reducing the number of experimental rounds needed to reach an optimal formulation.
Project Milestones
Each project is managed through clearly defined milestones, ensuring transparency and alignment with your development timeline. The exact duration depends on the number of optimization cycles required.
- Project Kickoff: Cargo assessment and specification of performance criteria. Agreement on project plan and deliverables.
- AI Screening & Design: Computational screening of lipid libraries and selection of top candidates for experimental testing.
- Prototype Formulation: Synthesis and characterization of initial LNP candidates. In vitro transfection data delivered.
- Optimization Cycles: Iterative refinement of formulation parameters based on characterization feedback. Each cycle includes synthesis, characterization, and testing.
- Final Deliverable: Optimized LNP formulation at requested scale, comprehensive characterization report, and recommendations for storage and handling.
Project timelines are discussed during the initial consultation and are customized based on the complexity of the formulation and desired iterations.
Quality Assurance and Analytical Rigor
Our LNP formulation services are built on a foundation of rigorous quality control and analytical characterization. Every formulation is tested for particle size, polydispersity index, zeta potential, and encapsulation efficiency using state-of-the-art instrumentation, including dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA).
We also assess stability under storage conditions and in biological fluids, ensuring that the LNP maintains its performance profile over time. In vitro transfection assays are conducted in multiple cell lines to confirm potency, and in vivo biodistribution studies can be performed as needed.
All data is documented in a comprehensive report that includes raw measurements, statistical analysis, and comparison to target specifications. This documentation supports your regulatory submissions and provides confidence in the reproducibility of the formulation.
Why Partner with Us for LNP Formulation Development
- AI-Driven Optimization: Our machine learning platform screens thousands of lipid combinations computationally, reducing the experimental burden and accelerating the path to an optimal formulation.
- Customized for Your Cargo: We design each LNP around your specific mRNA payload, adjusting lipid ratios and process parameters to achieve the highest encapsulation efficiency and delivery efficacy.
- Integrated End-to-End Support: From mRNA synthesis to LNP formulation, fill & finish, and analytical characterization, we offer a seamless integrated service that reduces handoffs and accelerates timelines.
- Regulatory-Ready Documentation: Our comprehensive characterization reports and quality control data are designed to support IND-enabling studies and regulatory submissions.
- Experienced Team: Our scientists have deep expertise in LNP formulation, lipid chemistry, and mRNA delivery, ensuring that your project benefits from cutting-edge knowledge and best practices.
Common In Vitro Cell Models for LNP Evaluation
We evaluate LNP formulations in a range of cell types that are relevant to the intended therapeutic target. The selection of cell models is guided by the delivery route and target tissue.
- Primary Hepatocytes: Commonly used for evaluating liver-targeted mRNA delivery, as hepatocytes are the primary cell type for many therapeutic applications.
- Dendritic Cells: Relevant for mRNA vaccine development, dendritic cells are key antigen-presenting cells that mediate immune responses.
- T Cells: Used for evaluating LNP-mediated delivery of mRNA encoding chimeric antigen receptors or other therapeutic proteins for cancer immunotherapy.
- HEK293 Cells: A widely used immortalized cell line for initial screening of LNP formulations due to high transfection efficiency and ease of culture.
- Huh-7 Cells: A liver-derived cell line that provides a relevant model for hepatic delivery and is often used for in vitro assessment of mRNA expression.
Contact Us
Whether you are developing a novel ionizable lipid, optimizing mRNA-to-lipid ratios, or scaling up a lead LNP formulation, our formulation scientists can help you design and evaluate the right approach for your therapeutic goals. Contact us today to discuss your project requirements.